Rybrevant

RYBREVANT- amivantamab injection
Janssen Biotech, Inc.

1 INDICATIONS AND USAGE

RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)] , whose disease has progressed on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients for treatment with RYBREVANT based on the presence of EGFR exon 20 insertion mutations [see Clinical Studies (14)]. Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics.

2.2 Recommended Dosage

The recommended doses of RYBREVANT, based on baseline body weight, are provided in Table 1, and the dosing schedule is provided in Table 2.

Table 1: Recommended Dose of RYBREVANT Based on Baseline Body Weight
Body Weight at Baseline * Recommended Dose Number of 350 mg/7 mL RYBREVANT Vials
*
Dose adjustments not required for subsequent body weight changes.
Less than 80 kg 1050 mg 3
Greater than or equal to 80 kg 1400 mg 4
Table 2: Dosing schedule for RYBREVANT
Weeks Schedule
Weeks 1 to 4 Weekly (total of 4 doses)
Week 1 — split infusion on Day 1 and Day 2
Weeks 2 to 4 — infusion on Day 1
Week 5 onwards Every 2 weeks starting at Week 5

Administer premedications before each RYBREVANT infusion as recommended [see Dosage and Administration (2.3)]. Administer diluted RYBREVANT intravenously according to the infusion rates in Table 6, with the initial dose as a split infusion on Week 1 on Day 1 and Day 2 [see Dosage and Administration (2.5), (2.6)]. Administer RYBREVANT until disease progression or unacceptable toxicity.

2.3 Recommended Premedications

Prior to initial infusion of RYBREVANT (Week 1, Days 1 and 2), administer premedication as described in Table 3 to reduce the risk of infusion-related reactions: [see Warnings and Precautions (5.1)]

Table 3: Premedications
Medication Dose Route of Administration Dosing Window Prior to RYBREVANT Administration
*
Required at all doses.
Required at initial dose (Week 1, Days 1 and 2); optional for subsequent doses.
Antihistamine * Diphenhydramine (25 to 50 mg) or equivalent Intravenous 15 to 30 minutes
Oral 30 to 60 minutes
Antipyretic * Acetaminophen (650 to 1,000 mg) Intravenous 15 to 30 minutes
Oral 30 to 60 minutes
Glucocorticoid Dexamethasone (10 mg) or Methylprednisolone (40 mg) or equivalent Intravenous 45 to 60 minutes

Administer both antihistamine and antipyretic prior to all infusions. Glucocorticoid administration required for Week 1, Days 1 and 2 doses only and as necessary for subsequent infusions.

2.4 Dosage Modifications for Adverse Reactions

The recommended RYBREVANT dose reductions for adverse reactions (see Table 5) are listed in Table 4.

Table 4: RYBREVANT Dose Reductions for Adverse Reactions
Body Weight at Baseline Initial Dose 1st Dose Reduction 2nd Dose Reduction 3rd Dose Reduction
Less than 80 kg 1050 mg 700 mg 350 mg Discontinue RYBREVANT
Greater than or equal to 80 kg 1400 mg 1050 mg 700 mg

The recommended RYBREVANT dosage modifications for adverse reactions are provided in Table 5.

Table 5: Recommended RYBREVANT Dosage Modifications for Adverse Reactions
Adverse Reaction Severity Dosage Modifications
Infusion-related reactions (IRR) [see Warnings and Precautions (5.1)] Grade 1 to 2
  • Interrupt RYBREVANT infusion if IRR is suspected and monitor patient until reaction symptoms resolve.
  • Resume the infusion at 50% of the infusion rate at which the reaction occurred.
  • If there are no additional symptoms after 30 minutes, the infusion rate may be escalated (see Table 6).
  • Include corticosteroid with premedications for subsequent dose (see Table 3).
Grade 3
  • Interrupt RYBREVANT infusion and administer supportive care medications. Monitor patient until reaction symptoms resolve.
  • Resume the infusion at 50% of the infusion rate at which the reaction occurred.
  • If there are no additional symptoms after 30 minutes, the infusion rate may be escalated (see Table 6).
  • Include corticosteroid with premedications for subsequent dose (see Table 3). For recurrent Grade 3, permanently discontinue RYBREVANT.
Grade 4
  • Permanently discontinue RYBREVANT.
Interstitial Lung Disease (ILD)/pneumonitis [see Warnings and Precautions (5.2)]. Any Grade
  • Withhold RYBREVANT if ILD/pneumonitis is suspected.
  • Permanently discontinue RYBREVANT if ILD/pneumonitis is confirmed.
Dermatologic Adverse Reactions (including dermatitis acneiform, pruritus, dry skin) [see Warnings and Precautions (5.3)] Grade 2
  • Initiate supportive care management.
  • Reassess after 2 weeks; if rash does not improve, consider dose reduction.
Grade 3
  • Withhold RYBREVANT and initiate supportive care management.
  • Upon recovery to ≤ Grade 2, resume RYBREVANT at reduced dose.
  • If no improvement within 2 weeks, permanently discontinue treatment.
Grade 4
  • Permanently discontinue RYBREVANT
Severe bullous, blistering or exfoliating skin conditions (including toxic epidermal necrolysis (TEN)
  • Permanently discontinue RYBREVANT.
Other Adverse Reactions [see Adverse Reactions (6.1)] Grade 3
  • Withhold RYBREVANT until recovery to ≤ Grade 1 or baseline.
  • Resume at the same dose if recovery occurs within 1 week.
  • Resume at reduced dose if recovery occurs after 1 week but within 4 weeks.
  • Permanently discontinue if recovery does not occur within 4 weeks.
Grade 4
  • Withhold RYBREVANT until recovery to ≤Grade 1 or baseline.
  • Resume at reduced dose if recovery occurs within 4 weeks.
  • Permanently discontinue if recovery does not occur within 4 weeks.
  • Permanently discontinue for recurrent Grade 4 reactions.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.